Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy

BACKGROUND: To minimise placental transfer of tumour necrosis factor inhibitors (TNFi), the European League Against Rheumatism (EULAR) created points to consider (PtC) for the use of TNFi during pregnancy. We are the first to validate the EULAR-PtC by analysing TNFi concentrations in cord blood. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghalandari, Nafise, Kemper, Erik, Crijns, Ineke (Hubertina), Wolbink, Gertjan, Rispens, Theo, Smeele, Hieronymus TW, Dolhain, Radboud JEM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862049/
https://www.ncbi.nlm.nih.gov/pubmed/34493490
http://dx.doi.org/10.1136/annrheumdis-2021-221036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862049/
https://www.ncbi.nlm.nih.gov/pubmed/34493490
http://dx.doi.org/10.1136/annrheumdis-2021-221036

Ejemplares similares